Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

Autor: Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman

Publikováno v: npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)

Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in

Externí odkaz: https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

Autor: Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman

Publikováno v: npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)

Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono

Externí odkaz: https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8

Trend in Clinical Trial Participation During COVID-19: A Secondary Analysis of the I-SPY COVID Clinical Trial

Autor: Philip Yang, MD, MSc, Neal W. Dickert, MD, PhD, Angela Haczku, MD, PhD, Christine Spainhour, RN, CCRC, Sara C. Auld, MD, MSc, the I-SPY COVID Consortium, Neil R. Aggarwal, MD, MHSc, Timothy Albertson, MD, Sara Auld, MD, Jeremy R. Beitler, MD, MPH, Paul Berger, DO, Ellen L. Burnham, MD, Carolyn S. Calfee, MD, MAS, Nathan Cobb, MD, Alessio Crippa, PhD, Andrea Discacciati, PhD, Martin Eklund, PhD, Laura Esserman, MD, MBA, D. Clark Files, MD, Eliot Friedman, MD, Sheetal Gandotra, MD, Kashif Khan, MD, Jonathan Koff, MD, Santhi Kumar, MD, Kathleen D. Liu, MD, PhD, Thomas R. Martin, MD, Michael A. Matthay, MD, Nuala J. Meyer, MD, Timothy Obermiller, MD, MS, Philip Robinson, MD, Derek Russell, MD, Karl Thomas, MD, Se Fum Wong, MD, Richard G. Wunderink, MD, Mark M. Wurfel, PhD, MD, Albert Yen, MD, Fady A. Youssef, MD, Anita Darmanian, MD, Amy L. Dzierba, PharmD, Ivan Garcia, RRT, Katarzyna Gosek, PharmD, Purnema Madahar, MD, MS, Aaron M. Mittel, MD, Justin Muir, PharmD, Amanda Roden, MD, John Schicchi, MD, Alexis L. Serra, MD, MPH, Romina Wahab, MD, Kevin W. Gibbs, MD, Leigha Landreth, RN, Mary LaRose, RN, Lisa Parks, RN, Adina Wynn, MPH, CCRP, Caroline A. G. Ittner, PhD, Nilam S. Mangalmurti, MD, John P. Reilly, MD, MS, Donna Harris, BSN, Abhishek Methukupally, MBBS, Siddharth Patel, MBBS, MPH, Lindsie Boerger, BA, John Kazianis, MD, Carrie Higgins, Jeff McKeehan, MS, Brian Daniel, RCP, RRT, Scott Fields, PharmD, James Hurst-Hopf, MS, Alejandra Jauregui, BA, Lamorna Brown Swigart, PhD, Daniel Belvins, CCRP, Catherine Nguyen, MD, Alexis Suarez, MS, Maged A. Tanios, MD, Farjad Sarafian, MD, Usman Shah, MD, Max Adelman, MD, MSc, Christina Creel-Bulos, MD, Joshua Detelich, MD, Gavin Harris, MD, Katherine Nugent, MD, Philip Yang, MD, Erin Hardy, Richart Harper, MD, Brian Morrissey, MD, Christian Sandrock, MD, MPH, G. R. Scott Budinger, MD, Helen K. Donnelly, RN, BSN, Benjamin D. Singer, MD, Ari Moskowitz, MD, Melissa Coleman, MD, Joseph Levitt, MD, Ruixiao Lu, PhD, Paul Henderson, PhD, Adam Asare, PhD, Imogene Dunn, PhD, Alejandro Botello Barragan

Publikováno v: Critical Care Explorations, Vol 5, Iss 6, p e0930 (2023)

OBJECTIVES:. To analyze the temporal trend in enrollment rates in a COVID-19 platform trial during the first three waves of the pandemic in the United States. DESIGN:. Secondary analysis of data from the I-SPY COVID randomized controlled trial (RCT).

Externí odkaz: https://doaj.org/article/7af4c25ca81249e2a0432daa16bb510e

Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study

Autor: Mark Jesus M. Magbanua, Laura van ‘t Veer, Amy S. Clark, A. Jo Chien, Judy C. Boughey, Hyo S. Han, Anne Wallace, Heather Beckwith, Minetta C. Liu, Christina Yau, E. Paul Wileyto, Andrea Ordonez, Tulasi I. Solanki, Feng Hsiao, Jen Chieh Lee, Amrita Basu, Lamorna Brown Swigart, Jane Perlmutter, Amy L. Delson, Lauren Bayne, Shannon Deluca, Stephanie S. Yee, Erica L. Carpenter, Laura J. Esserman, John W. Park, Lewis A. Chodosh, Angela DeMichele

Publikováno v: Breast Cancer Research and Treatment. 198:383-390

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4d5d9594333706082d8c23f09f69d3ae
https://doi.org/10.1007/s10549-022-06803-0

Figure S1 from MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype

Autor: Gerard I. Evan, Trevor D. Littlewood, Mark J. Arends, Laura Soucek, Lamorna Brown Swigart, Panayiotis Anastasiou, Steven Kupczak, Luca Pellegrinet, Tania Campos, Valentin J.A. Barthet, Roderik M. Kortlever, Nicole M. Sodir

MycERT2 expression in pancreata of Mpdx1 and Mp48 mice is at a level comparable to that of endogenous c-Myc in proliferating neonatal pancreas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1369634b3e6aac2bd088a54e80c2cf07
https://doi.org/10.1158/2159-8290.22535044.v1